Answers are grounded in this paper and cite their sources.
Background/Aim: γδ T cells, particularly the Vγ9Vδ2 subset, can recognize and directly kill cancer cells. γδ T-cell infusion can be autologous or allogeneic, but cancer cells employ various defense mechanisms against immune attack. This study evaluated the in vitro cytotoxic activity of patient-derived γδ T cells against urinary bladder cancer (UBC) cells and investigated TIM-3 expression and the effects of TIM-3 blockade on γδ T-cell cytotoxicity. Materials and Methods: Peripheral blood mononuclear cells (PBMCs) from UBC patients and healthy volunteers (HVs) were expanded ex vivo for 11 days and assessed for Vγ9Vδ2 T-cell expansion, differentiation, and cytotoxicity against cancer cells in vitro. Surface expression of checkpoint molecules on γδ T cells was also analyzed. Results: Ex vivo-expanded γδ T cells from UBC patients expanded and differentiated into Vγ9Vδ2 T cells as efficiently as those from HVs but showed weaker cytotoxicity against UBC cells. TIM-3 was consistently and highly expressed throughout γδ T-cell expansion. Blocking TIM-3 signaling significantly increased the cytotoxicity of allogeneic HV-derived γδ T cells against UBC cells in vitro, although a similar effect was not observed in a small number of patient-derived samples tested. Conclusion: Ex vivo-expanded autologous γδ T cells from UBC patients expanded and differentiated normally but showed reduced cytotoxicity. Targeting TIM-3 enhanced the cytotoxicity of allogeneic Vγ9Vδ2 T cells in vitro, suggesting a promising strategy for improving allogeneic γδ T-cell-based immunotherapy for UBC; whether TIM-3 blockade similarly benefits patient-derived γδ T cells remains to be determined.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: